Cargando…

Evaluating Montréal’s harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis

INTRODUCTION: The main harm reduction interventions for people who inject drugs (PWID) are supervised injection facilities, needle and syringe programmes and opioid agonist treatment. Current evidence supporting their implementation and operation underestimates their usefulness by excluding skin, so...

Descripción completa

Detalles Bibliográficos
Autores principales: Panagiotoglou, Dimitra, Abrahamowicz, Michal, Buckeridge, David L, Caro, J Jaime, Latimer, Eric, Maheu-Giroux, Mathieu, Strumpf, Erin C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549659/
https://www.ncbi.nlm.nih.gov/pubmed/34702731
http://dx.doi.org/10.1136/bmjopen-2021-053191
_version_ 1784590814626709504
author Panagiotoglou, Dimitra
Abrahamowicz, Michal
Buckeridge, David L
Caro, J Jaime
Latimer, Eric
Maheu-Giroux, Mathieu
Strumpf, Erin C
author_facet Panagiotoglou, Dimitra
Abrahamowicz, Michal
Buckeridge, David L
Caro, J Jaime
Latimer, Eric
Maheu-Giroux, Mathieu
Strumpf, Erin C
author_sort Panagiotoglou, Dimitra
collection PubMed
description INTRODUCTION: The main harm reduction interventions for people who inject drugs (PWID) are supervised injection facilities, needle and syringe programmes and opioid agonist treatment. Current evidence supporting their implementation and operation underestimates their usefulness by excluding skin, soft tissue and vascular infections (SSTVIs) and anoxic/toxicity-related brain injury from cost-effectiveness analyses (CEA). Our goal is to conduct a comprehensive CEA of harm reduction interventions in a setting with a large, dispersed, heterogeneous population of PWID, and include prevention of SSTVIs and anoxic/toxicity-related brain injury as measures of benefit in addition to HIV, hepatitis C and overdose morbidity and mortalities averted. METHODS AND ANALYSIS: This protocol describes how we will develop an open, retrospective cohort of adult PWID living in Québec between 1 January 2009 and 31 December 2020 using administrative health record data. By complementing this data with non-linkable paramedic dispatch records, regional monthly needle and syringe dispensation counts and repeated cross-sectional biobehavioural surveys, we will estimate the hazards of occurrence and the impact of Montréal’s harm reduction interventions on the incidence of drug-use-related injuries, infections and deaths. We will synthesise results from our empirical analyses with published evidence to simulate infections and injuries in a hypothetical population of PWID in Montréal under different intervention scenarios including current levels of use and scale-up, and assess the cost-effectiveness of each intervention from the public healthcare payer’s perspective. ETHICS AND DISSEMINATION: This study was approved by McGill University’s Institutional Review Board (Study Number: A08-E53-19B). We will work with community partners to disseminate results to the public and scientific community via scientific conferences, a publicly accessible report, op-ed articles and open access peer-reviewed journals.
format Online
Article
Text
id pubmed-8549659
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-85496592021-10-29 Evaluating Montréal’s harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis Panagiotoglou, Dimitra Abrahamowicz, Michal Buckeridge, David L Caro, J Jaime Latimer, Eric Maheu-Giroux, Mathieu Strumpf, Erin C BMJ Open Health Services Research INTRODUCTION: The main harm reduction interventions for people who inject drugs (PWID) are supervised injection facilities, needle and syringe programmes and opioid agonist treatment. Current evidence supporting their implementation and operation underestimates their usefulness by excluding skin, soft tissue and vascular infections (SSTVIs) and anoxic/toxicity-related brain injury from cost-effectiveness analyses (CEA). Our goal is to conduct a comprehensive CEA of harm reduction interventions in a setting with a large, dispersed, heterogeneous population of PWID, and include prevention of SSTVIs and anoxic/toxicity-related brain injury as measures of benefit in addition to HIV, hepatitis C and overdose morbidity and mortalities averted. METHODS AND ANALYSIS: This protocol describes how we will develop an open, retrospective cohort of adult PWID living in Québec between 1 January 2009 and 31 December 2020 using administrative health record data. By complementing this data with non-linkable paramedic dispatch records, regional monthly needle and syringe dispensation counts and repeated cross-sectional biobehavioural surveys, we will estimate the hazards of occurrence and the impact of Montréal’s harm reduction interventions on the incidence of drug-use-related injuries, infections and deaths. We will synthesise results from our empirical analyses with published evidence to simulate infections and injuries in a hypothetical population of PWID in Montréal under different intervention scenarios including current levels of use and scale-up, and assess the cost-effectiveness of each intervention from the public healthcare payer’s perspective. ETHICS AND DISSEMINATION: This study was approved by McGill University’s Institutional Review Board (Study Number: A08-E53-19B). We will work with community partners to disseminate results to the public and scientific community via scientific conferences, a publicly accessible report, op-ed articles and open access peer-reviewed journals. BMJ Publishing Group 2021-10-26 /pmc/articles/PMC8549659/ /pubmed/34702731 http://dx.doi.org/10.1136/bmjopen-2021-053191 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Health Services Research
Panagiotoglou, Dimitra
Abrahamowicz, Michal
Buckeridge, David L
Caro, J Jaime
Latimer, Eric
Maheu-Giroux, Mathieu
Strumpf, Erin C
Evaluating Montréal’s harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis
title Evaluating Montréal’s harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis
title_full Evaluating Montréal’s harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis
title_fullStr Evaluating Montréal’s harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis
title_full_unstemmed Evaluating Montréal’s harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis
title_short Evaluating Montréal’s harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis
title_sort evaluating montréal’s harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis
topic Health Services Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549659/
https://www.ncbi.nlm.nih.gov/pubmed/34702731
http://dx.doi.org/10.1136/bmjopen-2021-053191
work_keys_str_mv AT panagiotogloudimitra evaluatingmontrealsharmreductioninterventionsforpeoplewhoinjectdrugsprotocolforobservationalstudyandcosteffectivenessanalysis
AT abrahamowiczmichal evaluatingmontrealsharmreductioninterventionsforpeoplewhoinjectdrugsprotocolforobservationalstudyandcosteffectivenessanalysis
AT buckeridgedavidl evaluatingmontrealsharmreductioninterventionsforpeoplewhoinjectdrugsprotocolforobservationalstudyandcosteffectivenessanalysis
AT carojjaime evaluatingmontrealsharmreductioninterventionsforpeoplewhoinjectdrugsprotocolforobservationalstudyandcosteffectivenessanalysis
AT latimereric evaluatingmontrealsharmreductioninterventionsforpeoplewhoinjectdrugsprotocolforobservationalstudyandcosteffectivenessanalysis
AT maheugirouxmathieu evaluatingmontrealsharmreductioninterventionsforpeoplewhoinjectdrugsprotocolforobservationalstudyandcosteffectivenessanalysis
AT strumpferinc evaluatingmontrealsharmreductioninterventionsforpeoplewhoinjectdrugsprotocolforobservationalstudyandcosteffectivenessanalysis